tirzepatide diabetes trial New research from the SURPASS-EARLY found that improved glycemic control, body weight, and waist circumference over 104 weeks compared with intensified conventional care in adults with early type 2 SURPASS-CVOT Published: Large Trial Confirms
Description
The American Diabetes Association (ADA) and American Association of Clinical Endocrinologists recommend against combination therapy with a DPP4-inhibitor and a GLP-1 RA due to the lack of evidence that this strategy is beneficial
Can you take GLP-1 medications without diabetes
Whats the difference between Wegovy and Mounjaro for prediabetes
The exact amount varies by individual, but rebound typically begins within 2-4 weeks of stopping the medication as appetite hormones reactivate
Discuss any concerns with your GP or diabetes specialist nurse
Consult your doctor to understand which medication will be most suitable for you 1 , 2
